Malvern, PA, January 1, 2015 — Dr. Tim Henkel has joined Venatorx Pharmaceuticals as Chief Medical Officer. Dr. Henkel has spent 20 years in the biopharmaceutical industry developing antibacterial, antifungal, antiviral, immunomodulatory and oncology drugs. He has successfully developed biologics, small molecules and natural products in the US and Europe. Prior to joining Venatorx, Dr. Henkel was Executive Vice President of Research and Development at Ceptaris Therapeutics (acquired by Actelion).  Dr. Henkel was also Executive Vice President of Research and Development at Ception Therapeutics (acquired by Cephalon), Executive Vice President and Chief Medical Officer of Vicuron Pharmaceuticals (acquired by Pfizer), and Vice President of Worldwide Anti-Infective Clinical Development for SmithKline Beecham.

Prior to joining SmithKline Beecham, Dr. Henkel was Assistant Professor of Internal Medicine and Infectious Diseases at Washington University in St. Louis, where he also earned his board certifications in both Internal Medicine and in Infectious Diseases. He received his MD degree and a PhD in immunology from Washington University in St. Louis, and his BS in Chemistry and Biology from Rhodes College.